These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 29423660

  • 1. Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.
    Yu C, An M, Jones E, Liu H.
    Pharm Res; 2018 Feb 08; 35(3):56. PubMed ID: 29423660
    [Abstract] [Full Text] [Related]

  • 2. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C, An M, Li M, Liu H.
    Mol Pharm; 2017 Aug 07; 14(8):2815-2823. PubMed ID: 28686452
    [Abstract] [Full Text] [Related]

  • 3. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, von Bubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A.
    Eur J Immunol; 2006 Jan 07; 36(1):12-20. PubMed ID: 16323249
    [Abstract] [Full Text] [Related]

  • 4. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
    Nakagawa T, Tanino T, Onishi M, Tofukuji S, Kanazawa T, Ishioka Y, Itoh T, Kugimiya A, Katayama K, Yamamoto T, Nagira M, Ishii KJ.
    Front Immunol; 2021 Jan 07; 12():803090. PubMed ID: 35003132
    [Abstract] [Full Text] [Related]

  • 5. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity.
    Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH.
    Immunology; 2008 Jan 07; 123(1):118-28. PubMed ID: 17961163
    [Abstract] [Full Text] [Related]

  • 6. Targeted Delivery of Immunostimulatory CpG Oligodeoxynucleotides to Antigen-Presenting Cells in Draining Lymph Nodes by Stearic Acid Modification and Nanostructurization.
    Nagaoka M, Liao W, Kusamori K, Nishikawa M.
    Int J Mol Sci; 2022 Jan 25; 23(3):. PubMed ID: 35163272
    [Abstract] [Full Text] [Related]

  • 7. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
    Inoue J, Aramaki Y.
    Vaccine; 2007 Jan 22; 25(6):1007-13. PubMed ID: 17049678
    [Abstract] [Full Text] [Related]

  • 8. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
    Wilson KD, Raney SG, Sekirov L, Chikh G, deJong SD, Cullis PR, Tam YK.
    Int Immunopharmacol; 2007 Aug 22; 7(8):1064-75. PubMed ID: 17570323
    [Abstract] [Full Text] [Related]

  • 9. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
    Shima F, Uto T, Akagi T, Akashi M.
    Bioconjug Chem; 2013 Jun 19; 24(6):926-33. PubMed ID: 23631730
    [Abstract] [Full Text] [Related]

  • 10. Multiple Immunosuppressive Effects of CpG-c41 on Intracellular TLR-Mediated Inflammation.
    Liu W, Yang X, Wang N, Fan S, Zhu Y, Zheng X, Li Y.
    Mediators Inflamm; 2017 Jun 19; 2017():6541729. PubMed ID: 28539706
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.
    He LZ, Weidlick J, Sisson C, Marsh HC, Keler T.
    Cell Mol Immunol; 2015 Nov 19; 12(6):719-28. PubMed ID: 25345808
    [Abstract] [Full Text] [Related]

  • 13. Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.
    Zhang W, An M, Xi J, Liu H.
    Bioconjug Chem; 2017 Jul 19; 28(7):1993-2000. PubMed ID: 28644608
    [Abstract] [Full Text] [Related]

  • 14. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells.
    Booth JS, Nichani AK, Benjamin P, Dar A, Krieg AM, Babiuk LA, Mutwiri GK.
    Vet Immunol Immunopathol; 2007 Jan 15; 115(1-2):24-34. PubMed ID: 17067685
    [Abstract] [Full Text] [Related]

  • 15. Synthetic oligonucleotides as modulators of inflammation.
    Klinman D, Shirota H, Tross D, Sato T, Klaschik S.
    J Leukoc Biol; 2008 Oct 15; 84(4):958-64. PubMed ID: 18430787
    [Abstract] [Full Text] [Related]

  • 16. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B, Tincer G, Almacioglu K, Alpdundar E, Gursel M, Gursel I.
    J Control Release; 2017 Feb 10; 247():134-144. PubMed ID: 28069554
    [Abstract] [Full Text] [Related]

  • 17. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
    Klinman DM, Zeuner R, Yamada H, Gursel M, Currie D, Gursel I.
    Ann N Y Acad Sci; 2003 Dec 10; 1002():112-23. PubMed ID: 14751829
    [Abstract] [Full Text] [Related]

  • 18. Pivotal role of ADP-ribosylation factor 6 in Toll-like receptor 9-mediated immune signaling.
    Wu JY, Kuo CC.
    J Biol Chem; 2012 Feb 03; 287(6):4323-34. PubMed ID: 22170068
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
    Corogeanu D, Zaki K, Beavil AJ, Arnold JN, Diebold SS.
    PLoS One; 2023 Feb 03; 18(3):e0282831. PubMed ID: 36913398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.